China SXT Pharmaceuticals

Historical price data

China SXT Pharmaceuticals (NASDAQ: SXTC) is a China-based specialty pharmaceutical company with a dual-mission to modernize Traditional Chinese Medicine (TCM) and produce generic drugs. The company has established an integrated operational model, managing R&D, manufacturing, and commercialization in-house, primarily targeting high-prevalence conditions in its domestic market. Its strategy hinges on capitalizing on government support for TCM integration into the healthcare system and the ongoing demand for affordable generic pharmaceuticals, though it faces significant execution and competitive risks.

An integrated pharmaceutical development and manufacturing platform that applies modern standardization, quality control, and formulation sciences to Traditional Chinese Medicine (TCM) and utilizes standard bioequivalence and production processes for generic drugs.

SXT competes in fragmented markets against much larger players. In TCM, it faces established giants like Tasly and Yunnan Baiyao, while in generics, it contends with low-cost leaders like Hengrui in a price-war environment driven by government bulk-buying programs.